论文部分内容阅读
拓扑替康 (TPT)是一种公认的具有拓扑异构酶 I活性的治疗复发性卵巢癌的抗肿瘤药物。骨髓毒性与患者所接受的TPT日量有关 ,研究者们正在探索制订新的治疗方案 ,包括TPT每周 1次给药的方法。本研究的目的旨在确定 TPT治疗卵巢癌的每周 1次方案的患者最大耐受剂量。对已采用过一?
Topotecan (TPT) is a well-established antineoplastic agent for the treatment of recurrent ovarian cancer with topoisomerase I activity. Myelotoxicity is related to the amount of TPT received in patients and investigators are exploring the development of new treatment options, including TPT once a week. The purpose of this study was to determine the maximal tolerated dose of TPT for patients receiving a once-weekly regimen of ovarian cancer. Have you used one?